Pacer Advisors
STOK icon

Pacer Advisors’s Stoke Therapeutics STOK Stock Holding History

Pacer Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Buy
+731
New +$23.5K ﹤0.01% 2221
2024
Q3 		– Sell
-454
Closed -$6.13K – 2689
2024
Q2 		$6.13K Buy
+454
New +$6.13K ﹤0.01% 3618
2021
Q2 		– Sell
-811
Closed -$31K – 1547
2021
Q1 		$31K Buy
811
+384
+90% +$21.9K ﹤0.01% 1477
2020
Q4 		$26K Buy
+427
New +$19.6K ﹤0.01% 1470

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pacer Advisors's STOK Position: Q2 2026 in Review

Pacer Advisors opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 731 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #2221 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in STOK as recently as Q2 2024.

Pacer Advisors first reported a position in STOK in Q4 2020 and has held it in 4 quarters since. The position peaked at $31K in Q1 2021. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Pacer Advisors held 731 shares of Stoke Therapeutics worth $24K as of Q2 2026.
  • Stoke Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2221 holding.
  • Pacer Advisors first reported a position in Stoke Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • Pacer Advisors's Stoke Therapeutics position peaked at $31K in Q1 2021.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.